Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)

Market Cap	419.75M
Revenue (ttm)	199.68M
Net Income (ttm)	26.80M
Shares Out	n/a
EPS (ttm)	0.64
PE Ratio	15.66
Forward PE	n/a
Dividend	0.30 (3.14%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	5
Open	10.00
Previous Close	9.50
Day's Range	10.00 - 10.00
52-Week Range	7.05 - 11.50
Beta	n/a
RSI	69.36
Earnings Date	Feb 6, 2026

About FRA:YB3

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation...

• Industry: Commercial Physical and Biological Research
• Founded: 1957
• Employees: 1,436
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YB3

Financial Performance

In 2024, FRA:YB3's revenue was 32.41 billion, an increase of 22.54% compared to the previous year's 26.45 billion. Earnings were 4.92 billion, a decrease of -10.97%.

Financial numbers in JPY